uproleselan + chemotherapy

Uproleselan + chemotherapy is an investigational combination regimen primarily studied in **acute myeloid leukemia (AML)**, especially in relapsed or refractory settings. Uproleselan (GMI-1271) is a novel, first-in-class **E-selectin antagonist**, a carbohydrate analog of sialyl Lewis^x^, that blocks E-selectin-mediated adhesion in the bone marrow microenvironment. This inhibition disrupts cell survival pathways that promote chemotherapy resistance, thereby sensitizing leukemic cells to chemotherapy and reducing relapse rates and chemotherapy-associated toxicities, such as severe oral mucositis[1][2][3][4][5][6][7][8][9]. In preclinical models and clinical trials, uproleselan demonstrates synergy with several chemotherapy agents (e.g., mitoxantrone, etoposide, cytarabine, fludarabine, idarubicin), showing improved survival and remission rates relative to chemotherapy alone[4][5][9]. Uproleselan is developed by GlycoMimetics and has received FDA Breakthrough Therapy Designation for relapsed/refractory AML[2]. Chemotherapy refers to several standard regimens used in AML, including MEC (mitoxantrone, etoposide, cytarabine), FAI (fludarabine, cytarabine, idarubicin), and 7+3 (cytarabine, idarubicin)[3][4][5][7]. This combination is under active investigation in multiple ongoing phase 1, 2, and 3 clinical trials.

Brand names

uproleselan

Other names

uproleselan + chemotherapy